The mechanism by which GSK-J4 sensitises breast cancer cells to PI3K inhibitor involves silencing the IGFBP5 gene, which confers a growth advantage upon PI3K inhibitor-resistant breast cancer cells [41]. Here, PIK3CA is linked to breast carcinoma.